INOTREM
9.1.2023 09:01:51 CET | Business Wire | Press release
Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today it received funding from the Crohn’s & Colitis Foundation’s IBD Ventures under a program to accelerate research and development that aim to improve the quality of life for patients with IBD. The funding will support the development of a new therapeutic approach in IBD focusing on the TREM-1 pathway.
The funding follows a R&D collaboration between Inotrem, and the Crohn’s & Colitis Foundation announced in April 2022. The R&D collaboration seeks to pave the way of a personalized medicine approach in IBD patients based on TREM-1. Under the terms of the agreement, Inotrem has access to data and bio-samples from Foundation’s IBD Plexus®, which is the largest IBD database in the US with data from over 25,000 patients. Lasting over 18 months, the project will be a cornerstone in the design of Inotrem’s first-in-human clinical study with INO-02.
There are today 10 million people worldwide suffering from IBD, and the need for new therapeutic options remains very strong. Approximately 30% of patients are unresponsive to existing therapies and even among the initial responders, in up to 10% the drugs lose efficacy over time. For a decade, Inotrem has been elucidating the biology of TREM-1 as a regulator of the immune response in both acute as well as chronic inflammatory diseases. TREM-1 is a potential important contributor to IBD pathophysiology and targeting this pathway may offer a new treatment option for IBD patients with immune dysregulation.
“We are grateful for the support of such a well-respected organization as The Crohn’s & Colitis Foundation. This funding will help us to expand our patented technology platform centered around the TREM-1 pathway and dedicated to developing new therapies for chronic inflammatory syndromes next to our existing modalities for acute diseases,” indicates Sven Zimmermann, CEO of Inotrem.
“Beyond the financial support, this is a strong recognition of Inotrem’s scientific leadership regarding the role of the TREM-1 pathway in inflammatory processes as well as our robust therapeutic approaches targeting that biological target,” says Marc Derive, Chief Scientific Officer and Cofounder of Inotrem.
About Inotrem
Inotrem S.A. is an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, nangibotide, with potential applications in a number of therapeutic indications such as septic shock and myocardial infarction. In parallel, Inotrem has also launched another program to develop a new therapeutic modality targeting chronic inflammatory diseases. The company was founded in 2013 by Dr Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sebastien Gibot and Dr Marc Derive. Inotrem is supported by leading European and North American investors. www.inotrem.com
About the Crohn’s & Colitis Foundation
The Crohn's & Colitis Foundation is the leading non-profit organization focused on both research and patient support for inflammatory bowel disease (IBD), with the mission of curing Crohn's disease and ulcerative colitis, and of improving the quality of life of the millions of Americans living with IBD. The Foundation’s work is dramatically accelerating the research process through investment in research initiatives, while also providing extensive educational and support resources for patients and their families, medical professionals, and the public. For more information, visit crohnscolitisfoundation.org, call 888-694-8872, or email info@crohnscolitisfoundation.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230109005241/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cambridge Drives a New Era of Digital Maturity for the Age of AI24.2.2026 08:10:00 CET | Press release
Updated Cambridge Primary and Lower Secondary Digital Literacy curricula provide future-facing framework for responsible AI and media literacyBold curriculum update empowers children to think critically, act responsibly and shape, not just consume, technology As digital literacy moves to the forefront of education reforms worldwide, the International Education group at Cambridge University Press & Assessment (Cambridge) today announces a major transformation of its Cambridge Primary and Lower Secondary Digital Literacy curricula, redefining what it means for young people to thrive in an AI-powered world. Designed for learners aged 5–14, the updated Cambridge Primary Digital Literacy and Lower Secondary Digital Literacy go beyond teaching children how to use technology. They foster digital maturity, equipping students with the judgement, critical thinking and confidence to decide why, when and how technology should be used. The refreshed curricula provide schools with a clear, future-fa
Cubans Protest EU Financing of Havana Regime Amid Rising Tensions24.2.2026 08:05:00 CET | Press release
Cubans from across the United States gathered today in Washington, D.C., outside the Delegation of the European Union, to denounce the EU’s complicity in financing Cuba’s communist state. Protesters held signs reading, “EU, don’t fund the dictatorship,” “Democracies should not fund dictatorships,” and “This march would get me killed in Cuba.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223106922/en/ Cubans from across the United States gathered yesterday in Washington, D.C., outside the Delegation of the European Union, to denounce the EU’s role in financing Cuba’s communist state. The demonstration featured leading Cuban opposition groups including the Assembly of the Cuban Resistance and Cuban Freedom March along with former Cuban political prisoners, Veterans of the Bay of Pigs, Florida State Senator Alexis Calatayud, Miss Universe Cuba 2025 Lina Luaces, and television personality Lili Estefan. Photo: Assembly of th
SOLUM and SPAR International extend agreement for ESL and Digital Signage24.2.2026 08:00:00 CET | Press release
SOLUM (KOSPI: 248070) and SPAR International have extended their agreement as Preferred Supplier for Electronic Shelf Labels (ESL) and Digital Signage. SPAR International’s Preferred Supplier program is designed to help SPAR-licensed organisations worldwide evaluate and adopt trusted, competitive solutions more efficiently. With this selection, SOLUM is positioned as an official partner supporting SPAR organisations with ESL and Digital Signage solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223240814/en/ SOLUM and SPAR International have extended their agreement as Preferred Supplier for Electronic Shelf Labels (ESL) and Digital Signage (Image: SOLUM) SOLUM can supply SPAR licensed organisations with advanced and durable ESL and E-Paper solutions, including the latest Newton Core+ and Newton E-Paper 32” Series, alongside Digital Signage tailored to different store environments and use cases. Digital Signage can
Epredia and Mindpeak Announce EU Distribution Agreement for AI-Powered Image Recognition in Cancer Diagnostics24.2.2026 08:00:00 CET | Press release
Epredia will add Mindpeak AI modules for pathology to its digital pathology portfolio, offering enhanced precision and speed in diagnostic image review Epredia, a global leader in precision cancer diagnostics and a subsidiary of PHC Holdings Corporation (TSE: 6523), and Mindpeak, a leading provider of artificial intelligence (AI) solutions for clinical and research pathology, today announced a distribution agreement to bring Mindpeak’s AI-based image recognition software to Epredia’s digital pathology customers in the European Union. As cancer cases increase and diagnostic processes become more complex, pathology laboratories are under pressure to speed up processes and reduce costs. Mindpeak’s AI technology delivers instant, pixel-level analysis of digital images of tissue samples, enabling objective and reproducible assessments in breast cancer, lung cancer, gastrointestinal pathology, biomarker quantification and exploratory research studies. These tools are designed to reduce varia
The Empire State Building Presents First-Ever Children’s Birthday Party Package for Celebrations at the Iconic Observatory Experience23.2.2026 15:13:00 CET | Press release
Express Access, Party Favors, and Private Room with Decorations and Ghirardelli Ice Cream Sundaes Parents who have looked for the best birthday party idea for their children have had their wish fulfilled. Today, the Empire State Building (ESB) announced the debut of its first-ever ESB Birthday Party Package for kids at the international icon’s Observatory as part of year-long 95th anniversary celebrations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223161708/en/ The Empire State Building Presents First-Ever Children’s Birthday Party Package for Celebrations at the Iconic Observatory Experience “From Lego playtime to Percy Jackson readers, children love the Empire State Building and now parents can give an unmatched experience to their children and their friends,” said Anthony E. Malkin, chairman and CEO of Empire State Realty Trust. “This birthday party package tops them all with an escorted visit through our world-fa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom